180 Life Sciences Corporate Media Kit

22 Faster Time to Market Lower Development Costs Targeted Clinical Trial Novel Therapeutic Target Significant Unmet Need Repurposing drugs previously proven safe (targeted Alzheimer’s & Schizophrenia) Drugs stimulate vagal nerve, leading to localized anti- inflammatory response, similar to nicotine’s MoA Existing therapies have occasional serious adverse effects and target the disease’s pathogenesis further downstream First clinical trial targeting patients who ceased smoking and developed ulcerative colitis Nicotine consumption protects against ulcerative colitis, lupus, and schizophrenia a7 nAChR Platform, a Novel Therapeutic Platform for UC Essential receptor in the neutral circuit controlled by the vagus nerve 180 Life Sciences Corp. www.180lifesciences.com Q4 2020